List of Small Molecule Pharmaceuticals Companies in Sweden - 36

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

AcuCort has developed and commercializes Zeqmelit™, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. Zeqmelit™ is approved in Sweden, Denmark, and Norway; and AcuCort has signed its first commercial agreement. Altogether, this strengthens the company's assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.se.

AlzeCure Pharma is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops new, innovative, and effective drugs with a goal to combat Alzheimer's disease.

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.

Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in patients diagnosed with a septic condition, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). About Orviglance (Mangoral) Orviglance* (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study. About Oncoral Oncoral is a novel oral irinotecan tablet in development. Irinotecan is a chemotherapy with established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Oncoral is initially developed for the treatment of gastric cancer, a cancer form with unmet needs and the opportunity for Orphan Drug status in the US and Europe. Following successful Phase 1 results, Phase 2 clinical development for Oncoral is in preparation. *Trademark is registered in Europe and several other markets and submitted for registration in the US.

Biosergen’s antifungal drug candidate, BSG005, is the fruit of a groundbreaking effort over the last two decades by SINTEF (one of Europe’s largest independent research organizations) and the Norwegian University of Science and Technology (NTNU) to develop an improved version of Nystatin, a naturally occurring fungicidal chemical in the bacterial strain Streptomyces noursei. Work that to date has been published in more than 20 international peer reviewed scientific publications. BSG005 has been shown to have a broad spectrum of action. At similar dose levels, the drug demonstrates a three to four times in vivo potency advantage over the current standard of care for patients not responding to Azole and Echinocandin treatment. With this product profile BSG005 will fill the need for a product that offers fungicidal efficacy against a broad range of fungal strains. BSG005 appears to be without the gaps due to resistance development seen in other antifungals. Most importantly, in the GLP-tox tests and in recognized animal models it lacks the severe kidney toxicity seen with Amphotericin B formulations. BSG005 has also shown effect against resistant fungal strains and strains that have been difficult to treat with the drugs available on the market.

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.

We are a Nordic biotechnology company with a broad pipeline of innovative groundbreaking drug candidates and derma cosmetic products. Our projects have great potential for treating patients with serious diseases such as cancer and diabetes complications and improving the quality of life for people in need of cosmetic products in hair growth. The strategy is to create value by developing and commercializing derma cosmetic products in partnership with significant commercial players and early handing over "first-in-class" drug candidates to larger pharmaceutical companies. Coegin Pharma has three established portfolio companies through Follicum AB, Reccura Therapeutics AS and Avexxin Oncology AS.

Cyxone AB (publ) is a clinical stage biotech company that develops new innovative therapies for the treatment of rheumatoid arthritis and multiple sclerosis. The company's goal is to improve the quality of life for patients with autoimmune and autoinflammatory diseases.

Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.

Dizlin Pharmaceuticals AB is a privately held Swedish research-based pharmaceutical development company with focus on diseases of the central nervous system in general and on developing improved treatment for advanced stages of Parkinson's disease in particular. The company conducts research in collaboration with researchers at the University of Gothenburg and Linköping University in Sweden. The company has developed a new patented method for treatment of advanced stages of Parkinson's disease. Dizlin Pharmaceuticals has two products in late phase development stage. The first - Infudopa IntraV™ – is administered intravenously to minimize risks associated with surgery on patients with Parkinson's disease. The second – Infudopa SubC™ – is administered as a continuous subcutaneous infusion by means of a portable pump (similar to insulin infusion for diabetes).

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

EQL Pharma AB (publ) is a pharmaceuticals company based out of Skåne County, Sweden.

Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell's first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable our world-leading partners to advance their drug-screening capabilities for the development of game-changing medicines.

Gedea Biotech develops pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can be very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge. Standard treatment consists of antimicrobials, but recurrence rate is 15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health and research into novel non-antimicrobial based treatments is timely.

Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.

Insufficient iron levels lead to fatigue, focus issues, headaches, heart palpitations, learning disabilities, and depression. Low iron not only impacts women and girls but also the elderly, children, vegetarians, vegans, and those with chronic illnesses. This, mainly female, problem can affect performance levels and cause productivity and income gaps between men and women from an early age in life. Ironic has developed a portfolio of patented non-animal heme iron compounds with absoption rates comparable to the iron in meat. We produce them sustainably through precision fermentation. Our product is tasteless and stable, so it can be taken as pills or mixed in foods. We are also working with food companies to add our bioavailable iron directly into food products.

Klaria AB is a pharmaceutical company developing innovative pharmaceuticals for migraine, cancer-related pain and opioid overdoses.

Medivir is a drug discovery and development company focusing on transformative cancer drugs. Their research and development are based on their extensive knowledge of protease inhibition and nucleoside/nucleotide science. The company is headquartered in Stockholm, Sweden.

Moberg Pharma is a specialist pharmaceutical company focused on commercializing innovative products for the treatment of common diseases. The company's goal is to make MOB-015 the world's leading treatment for nail fungus and to build a specialty pharmaceutical company with its own sales.

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.

Oblique Therapeutics AB (publ.) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses Abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information, visit: www.oncopeptides.com

PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company's drug candidate, PN6047, effectively reduces neuropathic pain in animal models and the findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 exhibited none of the adverse events typically associated with the conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or signs of abuse potential. This validates the unique preclinical profile of PN6047, which shows that it acts extremely selectively on the delta opioid receptor distinguishing it fundamentally from conventional opioids that target the mu opioid receptor. PN6047 is Phase II ready!

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market.

Recipharm is a leading global CDMO dedicated to meeting your evolving needs through operational excellence, scientific know-how, and customer connectivity. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering. Our worldwide reach paired with in-depth, localised market knowledge allows us to anticipate our customers’ needs and strengthen the support we provide to forge a healthier, more expansive and more fruitful future together. With a workforce of 5 200 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. Since our inception in 1995, we have supported our customers throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again to ensure their products are delivered with certainty.

SARomics Biostructures provides a broad range of structural biology and drug discovery services that include: X-ray crystallography services: Protein cloning, expression, characterization, and crystallization, FastLane™ Standard and FastLane™ Premium off-the-shelf structures, gene-to-structure services. Protein NMR spectroscopy: Peptide NMR & protein NMR assignment, peptide NMR & protein NMR structure determination, protein-ligand & protein-protein complex structure determination, fragment screening using 1D or 2D NMR spectroscopy, epitope mapping and dissociation constant (Kd) determinations for compounds, biosimilars higher order structure (HOS) verification & comparability analysis, formulation characterization and optimization, expression and purification of 2H, 15N, and 13C-labelled protein in E.coli for NMR spectroscopy studies and structure determination. Structure-based lead discovery services: Fragment screening and fragment-based drug design, computational chemistry, in silico drug discovery services. Our integrated drug discovery platform relies on our unique and proprietary weak affinity chromatography screening technology (WAC™). Antibody & antibody-antigen 3D structure determination, higher order structure (HOS) comparability analysis of biosimilars. Why choose SARomics Biostructures The commitments of our highly experienced and competent team of crystallographers, modelers, and molecular biologists include: Swift replies to all contact requests. After the initial project discussion, we provide realistic project timelines. We guarantee high quality services. We have a high degree of customer satisfaction. Our robust technology platform is built around a wide variety of experimental methods required in modern structural biology. We use a unique and verified proprietary method for compound screening. We benefit from an excellent location in Medicon Village in Lund and proximity to one of the world's best synchrotrons, MAX IV.

For customers working in the life sciences and pharma industry, Svar offers a unique combination of scientific expertise, high-quality assay products, strong services, and proprietary technology platforms that provide a flexible, effective, and seamless experience for customers through different development needs in a way that no other single business can. At Svar, we are dedicated to our customers' development journey. We harness a deep understanding and long-standing experience in immunological areas such as complement system activation and immunogenicity. We utilize this in our expert cell engineering, assay development, and contract research services capabilities. Our specialist knowledge allows us to help you tackle complex problems, safely and efficiently moving your candidates through the drug development phases and to the patient—also when standard solutions fall short.

SynAct Pharma is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral melanocortin receptor agonists for the treatment of inflammatory diseases. For more information, visit https://synactpharma.com/en/

Thioredoxin Systems AB is a biotechnology company developing a novel antibiotic regimen against pathogenic bacteria. EbsArgent is a patented combination of ebselen and silver, capable of functioning as an antiseptic, antibacterial in food production, and as a medicinal product. With its versatility and ability to act on a wide range of multi-drug resistant bacteria, it is among the most promising antibiotic regimen under development today.

Umecrine Cognition is a pharmaceutical company that is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's drug candidate, golexanolone, has a unique product profile that addresses important clinical needs and is also the only drug of its class under development. Umecrine Cognition is headquartered in Solna, Sweden and is focused on addressing important unmet medical needs in the field of central nervous system disorders.

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Xinnate is a young biopharmaceutical company built on groundbreaking scientific research about innate defence and healing mechanisms – evolutionary biological systems with the purpose of keeping us healthy. One of these innate defence peptides has shown to be an effective ”natural” and unique way of preventing infection as well as reducing excessive inflammation. Xinnate specializes in the development of proprietary peptide-based drugs for prevention and treatment of inflammatory diseases and infections within the areas skin and wounds, surgical materials and and biomaterials. The company was founded in 2019 and is based on 15 years of world class research from Lund University. The first area to be addressed by Xinnate is advanced wound care, and the first product is a hydrogel, the BioC wound gel, aimed for treatment of burn wounds.

Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients' quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval and has received orphan drug status in the US. Xspray Pharma's management team has extensive experience from the pharmaceutical industry. The company is based in Stockholm and shares are traded on Nasdaq Stockholm. www.xspraypharma.com